The Profound Impact of Duplex Sequencing: An Interview with Jesse Salk, CEO, TwinStrand Biosciences
Despite the recent progress in targeted cancer therapies, the frequent development of drug resistance has proved to be a major hindrance. Rare mutations acquired by a small population of cells could benefit tumorigenesis and be cancer’s ticket to back door entry. However, identifying them is a challenge owing to the high error rates of current sequencing tools. A powerful sequencing method dubbed ‘Duplex Sequencing’ could significantly minimize this problem. By sequencing both strands of individual DNA molecules, Duplex Sequencing can identify ultra-low frequency mutations with a 10,000-fold higher resolution. We interviewed Dr. Jesse Salk, CEO of TwinStrand, to learn more about the technique and its potential in advancing cancer research.
It's free! Log in now to read
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115